AIM:NYSEAMERICAN
AIM ImmunoTech Inc
US$ 0.19
arrow_upward
+1.53%(+0.0028) Siku 1
7 Okt, 15:13:05 GMT -4 · USD
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya AIM...
Fungua
US$ 0.18
Juu
US$ 0.19
Chini
US$ 0.18
Mtaji wa soko
7.50M
Wastani wa kiasi cha mauzo
8.76M
Kiasi cha mauzo ya hisa
elfu 481.50
Juu kwa wiki 52
US$ 2.88
Chini kwa wiki 52
US$ 0.17
EPS
-US$ 3.93
Beta
1.27
Hisa za wawekezaji
39.90M
Idadi ya wafanyakazi
20
Fungua
US$ 0.18
Juu
US$ 0.19
Chini
US$ 0.18
Mtaji wa soko
7.50M
Wastani wa kiasi cha mauzo
8.76M
Kiasi cha mauzo ya hisa
elfu 481.50
Juu kwa wiki 52
US$ 2.88
Chini kwa wiki 52
US$ 0.17
EPS
-US$ 3.93
Beta
1.27
Hisa za wawekezaji
39.90M
Idadi ya wafanyakazi
20
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Stock Titan
·
saa 6 zilizopita
Exploratory data found 34.8 months’ median survival in 39 patients with a low blood-cell ratio.
Yahoo Finance
·
saa 6 zilizopita
AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays
Stock Titan
·
siku 2 zilizopita
An experimental antiviral draws attention for a possible role against Ebola
Wasifu
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
Kuhusu AIM ImmunoTech Inc
Afisa Mkuu Mtendaji (CEO)-
Wafanyakazi20
Lilianzishwa1966
Makao makuuPhiladelphia, Pennsylvania, Marekani
Sekta-
Tovutiaimimmuno.com